Multicyclic dose-intensive chemotherapy with circulating progenitor cell support for high-risk primary breast cancer

Oncology Reports

Volumn 5, Issue 2, 1998, Pages 427-429

  Danova, M ^a,b   Perotti, C ^a   Mora, O ^a   Lucotti, C ^a   Torretta, L ^a   Comolli, G ^a   Riccardi, A ^a   Salvaneschi, L ^a   Ascari, E ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Università e IRCCS   (Italy)

Author keywords

Adjuvant therapy; Breast cancer; Circulating progenitor cells; G CSF; Multicyclic dose intensive chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLONY FORMING UNIT GM; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; PRIORITY JOURNAL; STEM CELL;

EID: 0031936555     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.2.427     Document Type: Article

References (16)

1. Vadhat L and Antman K: High-dose therapy for breast cancer. Blood Rev 9: 191-200, 1995.
2. Sheridan WP, Begley CG, Juttner CA, et al: Effect of peripheral blood progenitor cells mobilized by Filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339: 640-644, 1992.
3. Crown J, Kritz A, Vahadat L, et al: Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol 11: 1144-1149, 1993.
4. Venturini M, Del Mastro L, Melioli G, et al: Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony-stimulating factor for breast cancer therapy. Cancer 74: 2300-2306, 1994.
5. Torretta L, Perotti C, Dornini G, et al: Circulating progenitor cell collection: experience from 275 leukapherese in various malignancies and in healthy donors. Haematologica 81: 208-215, 1996.
6. Siena S, Bregni M, Brando B, et al: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77: 400-409, 1991.
7. Ardizzoni A, Venturini M, Sertoli MR, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: randomized study in patients with advanced breast cancer. Br J Cancer 69: 385-391, 1994.
8. Riccardi A, Giordano M, Brugnatelli S, et al: Advanced breast cancer: a randomized study of different doses of epirubicin associated with fixed doses of cyclophopshamide and 5-fluorouracil. Oncol Rep 2: 577-582, 1995.
9. Bisset D, Jodrell D, Hamett AN, et al: Phase I study of accelerated FEC with granulocyte colony-stimulating factor (lenograstim) support. Br J Cancer 71: 1279-1282, 1995.
10. Brufman G, Colajori E, Ghilezian N, et al: Doubling epirubicin dose intensity (100 mg/sqm vs 50 mg/sqm) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. Ann Oncol 8: 155-162, 1997.
11. Tepler I, Cannistra SA, Frei E III, et al: Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 11: 1583-1591, 1993.
12. Danova M, Rosti V, Mora O, et al: The use of peripheral blood hemopoietic progenitors mobilized with standard dose chemotherapy plus granulocyte colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast cancer. Oncol Rep 2: 1075-1078, 1995.
13. Basser RL, To LB, Begley CG, et al: Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blod progenitor cells. Clin Cancer Res 1: 715-721, 1995.
14. Meisenberg BR, Miller WE, McMillan R et al: Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 15: 11-17, 1997.
15. Gianni AM, Siena S, Bregni M, et al: Efficacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 15: 2312-2321, 1997.
16. Peters WP, Ross M, Vrenenburg JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11: 1132-1143, 1993.